Merck, R7752-250MG, Ristomycin monosulfate

General description
Ristomycin/ristocetin is a type III glycopeptide. It is a highly glycosylated glycopeptide, previously found in Amycolatopsis lurida.
Application
Ristomycin monosulfate has been used:
to activate platelet and induce platelet aggregation
to study the aggregation responses of platelets from buffalo, horse, pig and sheep
in in-house ristocetin cofactor von Willebrand factor (VWF:RCo) assay to measure glycoprotein Ib (GpIb) binding activity

Biochem/physiol Actions
Ristomycin possesses antibacterial activity. It may be used to diagnose von Willebrand disease and Bernard-Soulier syndrome. Ristocetin-induced platelet agglutination (RIPA) is decreased in patients undergoing chronic hemodialysis. Increased plasma glycocalicin levels (a product of enzymatic cleavage of GPIb) and decreased RIPA might reduce platelet adhesion to vascular subendothelium and improve bleeding associated with uremia in patients with chronic hemodialysis.
Ristocetin activates platelets. Ristocetin-induced platelet agglutination (RIPA) is decreased in patients undergoing chronic hemodialysis. Together with increased plasma glycocalicin levels (a product of enzymatic cleavage of GPIb), RIPA may contribute to diminished platelet adhesion to vascular subendothelium and increased bleeding associated with uremia. Addition of ristocetin and vWf caused specific agglutination of rGPIbα-liposomes suporting the potential use of rGPIbα-liposomes to enhance platelet function in vivo and support hemostasis in thrombocytopenic individuals.
Other Notes
Glycopeptide antibiotic complex